

**TRADEMARK ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNS THE ENTIRE INTEREST AND THE GOODWILL
EFFECTIVE DATE:	03/30/2006

**CONVEYING PARTY DATA**

Name	Formerly	Execution Date	Entity Type
Nanobac Life Sciences, Inc.		03/30/2006	CORPORATION: FLORIDA

**RECEIVING PARTY DATA**

Name:	Calgenex Corporation
Street Address:	9950 Princess Palm Avenue
City:	Tampa
State/Country:	FLORIDA
Postal Code:	33619
Entity Type:	CORPORATION: FLORIDA

**PROPERTY NUMBERS Total: 4**

Property Type	Number	Word Mark
Serial Number:	78727119	DERMALLEVE
Serial Number:	78731531	EDTA XL
Serial Number:	78639259	CALCI-CLEAR
Serial Number:	78740130	CRYSTAL CLEAR

**CORRESPONDENCE DATA**

Fax Number: (813)623-5625  
*Correspondence will be sent via US Mail when the fax attempt is unsuccessful.*  
 Phone: 813-623-5268  
 Email: jdm@calgenex.com  
 Correspondent Name: Jim Mosbaugh  
 Address Line 1: 9950 Princess Palm Avenue  
 Address Line 4: Tampa, FLORIDA 33619

NAME OF SUBMITTER: Jim Mosbaugh

OP \$115.00 78727119

Signature:

/Jim Mosbaugh/

Date:

03/30/2006

Total Attachments: 1

source=Agreement between NB Calgenex -Executed copy - 03 30 06#page1.tif

**NANOBAAC**

March 30, 2006

Grant Carlson  
Calgenex Corporation  
9950 Princess Palm Ave, Suite 320  
Tampa, FL 33619

Dear Mr. Carlson,

This letter is to confirm our telephone discussion on March 22, 2006. As I mentioned, Nanobac Pharmaceuticals, Inc. is changing its strategic focus. In an effort to focus its efforts on research and development, the Company will cease and desist to manufacture and market the Nanobac Oral Supplement and EDTA rectal suppositories.

Over the years we have acquired a small but loyal base of customers for the above named products. In addition, we have a number of customers that are part way through a four to six month regime of therapy. In an effort to maintain product availability, Nanobac will allow Calgenex and its pharmacy partner(s) to manufacture and market the same, or similar products, but will take no responsibility for the quality or medical impact of such products. This is not a license but rather a non exclusive permission to manufacture and market these products. Calgenex is responsible for conforming to government regulations associated with the manufacture and sale of such products and promises to hold harmless Nanobac for regulatory consequences resulting from the manufacture or sale of such products. Calgenex is not to imply to customers that it has a partnership or other business relationship with Nanobac. Nanobac retains the right to use its patents relating to these products for experimental therapies. It is agreed that these products will be marketed under a different name. Nanobac hereby assigns the rights to Calgenex for the following pending trademarks filed as *Intent to Use* applications: Cal-Detox, EDTA-XL, Calci-Clear, Crystal Clear and Dermalleve. These marks have not been used in commerce.

As part of this transition, Calgenex will take receipt of a pending order of one thousand (1,000) units of the Oral Supplement from Arnet Pharmaceuticals and will pay the outstanding invoice totaling eight thousand eight hundred eighty three dollars (\$8,883.00) plus shipping and handling. Furthermore, effective March 15, 2006, Calgenex will hire and assume total responsibility for sales and marketing personnel associated with the sales and marketing of the Nanobac Oral Supplement and EDTA rectal suppositories products. Nanobac will have no responsibility for them whatsoever.

Please sign and date this letter in the space provided below to indicate your agreement with the above, and return the original to me. Thank you for your willingness to maintain availability of this important product. I wish you great success.

Sincerely,

*Benedict S. Maniscalco*

Benedict S. Maniscalco  
Co-Chairman Nanobac Pharmaceuticals

Signature: *Grant Carlson*  
Grant Carlson

Date: 3/30/2006

*State Florida's  
Hilsherry  
03-30-06  
Hilsherry*

